Osteolysis Clinical Trial
Official title:
Denosumab for Treating Periprosthetic Osteolysis After Uncemented Total Hip Arthroplasty A Randomized, Double-blind, Placebo-controlled Trial Using Volumetric Computed Tomography
The main objective is to study the efficacy of denosumab in reducing wear-induced osteolysis around uncemented acetabular implants used in total hip arthroplasty. Patients included in the study will receive the same dose of 60 mg denosumab or placebo (1 ml solution) for a total of 6 doses with start on day one and every 6 months with last treatment at 30 months. The primary endpoint will be the change in volume of the osteolytic lesion over 3 years measured (measured with 3D-CT in cm³).
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01272830 -
Double-Blinded Clinical Trial Using Apatone®B for Symptomatic Postoperative Total Joint Replacements
|
Phase 2 | |
| Completed |
NCT00367289 -
CT for Diagnosis of Implant Stability in Revision Arthroplasty
|
N/A | |
| Recruiting |
NCT05018130 -
Bio-Integrative Versus Metallic Screws for Calcaneus Osteotomies
|
N/A | |
| Not yet recruiting |
NCT06041828 -
Regular Home-use Dual Light Photodynamic Therapy in the Prevention of Osteolysis After Dental Implant Surgery
|
N/A | |
| Terminated |
NCT01464645 -
Post-Market Study of the Modular Revision Hip System
|
||
| Completed |
NCT01198457 -
Study to Investigate Adherence of Patients to Clodronate (Bonefos) Treatment
|
N/A | |
| Active, not recruiting |
NCT04255966 -
Plasmafit® Revision Structan® Hip Endoprosthesis Cup
|